What is the goal of product surveillance in the pharmaceutical industry? Response:

Question

Options

• ATo monitor competitive product launches
• BTo ensure continuous patient safety and product efficacy
• CTo track the movement of pharmaceutical stocks
• DTo gather data for marketing analysis

• A
  15% (7)
• B
  72% (33)
• C
  9% (4)
• D
  4% (2)

Explanation

Product surveillance in pharmaceuticals is a post-market regulatory requirement focused on continuously monitoring a product's safety profile and therapeutic effectiveness after it reaches patients - making B the correct answer. This encompasses adverse event reporting, signal detection, and risk-benefit reassessment throughout a product's lifecycle.

Why the distractors are wrong:

• A (competitive launches) describes competitive intelligence, a business function unrelated to regulatory surveillance obligations.
• C (stock movement) is a financial/investor activity with no connection to pharmacovigilance or product oversight.
• D (marketing data) serves commercial strategy; while real-world data can inform marketing, it is not the goal of surveillance programs.

Memory tip: Think of product surveillance as the industry's ongoing "safety promise" to regulators and patients - it picks up where clinical trials leave off. If you remember "surveillance = safety after approval," you can eliminate any answer tied to competition, finance, or marketing.

No community discussion yet for this question.